Form 4: Bio-Rad COO's Stock Vesting & Tax Sale

Bio-Rad Laboratories' President & COO, Jonathan P. DiVincenzo, acquired shares through RSU vesting and sold a portion for tax obligations.

Summary

• Jonathan P. DiVincenzo, President & COO of Bio-Rad Laboratories, Inc., acquired 1,869 shares of Class A common stock on October 24, 2025, through the vesting of restricted stock units.
• Concurrently, 950 shares of Class A common stock were disposed of on October 24, 2025, at a price of $339.75 per share, likely to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, DiVincenzo directly owns 919 shares of Bio-Rad A Common Stock.
• DiVincenzo also beneficially owns 5,609 restricted stock units, with each unit representing a contingent right to receive one share of Bio-Rad Class A common stock.

Sentiment

Score: 6

Explanation: The filing reflects a routine executive compensation event involving the vesting of restricted stock units and a subsequent tax-related share disposition, which is a neutral event for the company's operational performance and generally expected.

Positives

• The vesting of 1,869 restricted stock units demonstrates the executive's continued tenure and the company's performance-based compensation structure, aligning executive interests with shareholder value.

Negatives

• The disposition of 950 shares, while primarily for tax purposes, reduces the executive's direct beneficial ownership of Class A common stock.

Future Outlook

The restricted stock units held by the executive vest over four years at 25% per year on the yearly anniversary date of the grant, indicating future share acquisitions through vesting.

Industry Context

This Form 4 filing details a routine executive compensation event, specifically the vesting of restricted stock units and a subsequent tax-related share sale. Such transactions are common across all industries for publicly traded companies as part of their executive incentive and compensation programs.

Stakeholder Impact

• Shareholders: The transaction is a routine compensation event with minimal direct impact on share price beyond market perception of insider activity. It reflects the ongoing compensation structure for executives.
• Employees: Reinforces the company's executive compensation structure, potentially signaling stability in leadership and adherence to established incentive plans.

Next Steps

• Future vesting of the remaining 5,609 restricted stock units according to the 25% per year schedule on their respective anniversary dates.

Key Dates

Recommendation

The Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax liabilities. This type of transaction is a standard part of executive compensation and does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation.

Keywords

Bio-Rad, BIO, BIO.B, Form 4, insider transaction, stock vesting, RSU, executive compensation, Jonathan P. DiVincenzo